相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Multiple Mutations and Bypass Mechanisms Can Contribute to Development of Acquired Resistance to MET Inhibitors
Jie Qi et al.
CANCER RESEARCH (2011)
Favorable response to crizotinib in three patients with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion-type oncogene-positive non-small cell lung cancer
Takashi Kijima et al.
CANCER SCIENCE (2011)
Semaphorin 4D, a lymphocyte semaphorin, enhances tumor cell motility through binding its receptor, plexinB1, in pancreatic cancer
Shingo Kato et al.
CANCER SCIENCE (2011)
The Ability to Form Primary Tumor Xenografts Is Predictive of Increased Risk of Disease Recurrence in Early-Stage Non-Small Cell Lung Cancer
Thomas John et al.
CLINICAL CANCER RESEARCH (2011)
Increased circulating hepatocyte growth factor (HGF): A marker of epithelial ovarian cancer and an indicator of poor prognosis
Guro Aune et al.
GYNECOLOGIC ONCOLOGY (2011)
METMutations in Cancers of Unknown Primary Origin (CUPs)
Giulia M. Stella et al.
HUMAN MUTATION (2011)
Plexin-B1 is a target of miR-214 in cervical cancer and promotes the growth and invasion of HeLa cells
Ran Qiang et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2011)
Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies
Timothy A. Yap et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Quantitative Phospho-Proteomic Profiling of Hepatocyte Growth Factor (HGF)-MET Signaling in Colorectal Cancer
Shawna L. Organ et al.
JOURNAL OF PROTEOME RESEARCH (2011)
Induction of MET by Ionizing Radiation and Its Role in Radioresistance and Invasive Growth of Cancer
Francesca De Bacco et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification
Sai-Hong Ignatius Ou et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patient
Sohei Yamamoto et al.
MODERN PATHOLOGY (2011)
A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma
Patrick Y. Wen et al.
NEURO-ONCOLOGY (2011)
The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
Nicole G. Chau et al.
HEAD & NECK ONCOLOGY (2011)
Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
Alexa B. Turke et al.
CANCER CELL (2010)
MK-2461, a Novel Multitargeted Kinase Inhibitor, Preferentially Inhibits the Activated c-Met Receptor
Bo-Sheng Pan et al.
CANCER RESEARCH (2010)
MET Receptor Sequence Variants R970C and T992I Lack Transforming Capacity
Jeffrey W. Tyner et al.
CANCER RESEARCH (2010)
Acquired Resistance of Non-Small Cell Lung Cancer Cells to MET Kinase Inhibition Is Mediated by a Switch to Epidermal Growth Factor Receptor Dependency
Ultan McDermott et al.
CANCER RESEARCH (2010)
MET and KRAS Gene Amplification Mediates Acquired Resistance to MET Tyrosine Kinase Inhibitors
Virna Cepero et al.
CANCER RESEARCH (2010)
Cell Signaling by Receptor Tyrosine Kinases
Mark A. Lemmon et al.
CELL (2010)
A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2
Joseph Paul Eder et al.
CLINICAL CANCER RESEARCH (2010)
Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor-Neutralizing Monoclonal Antibody, in a First-in-Human Study of Patients with Advanced Solid Tumors
Michael S. Gordon et al.
CLINICAL CANCER RESEARCH (2010)
Tyrosine Kinases as Molecular Targets to Inhibit Cancer Progression and Metastasis
V. Cepero et al.
CURRENT PHARMACEUTICAL DESIGN (2010)
Small molecule c-Met kinase inhibitors: a review of recent patents
John Porter
EXPERT OPINION ON THERAPEUTIC PATENTS (2010)
American Society of Clinical Oncology 2010: report of selected studies from the CNS tumors section
Patrick Y Wen
Expert Review of Anticancer Therapy (2010)
Results from ARQ 197-209: A global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
J. H. Schiller et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Plexin B1 Suppresses c-Met in Melanoma: A Role for Plexin B1 as a Tumor-Suppressor Protein through Regulation of c-Met
Laurel Stevens et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2010)
Clinical Value of Plasma Hepatocyte Growth Factor Measurement for the Diagnosis of Periampullary Cancer and Prognosis After Pancreaticoduodenectomy
Omar Barakat et al.
JOURNAL OF SURGICAL ONCOLOGY (2010)
Comprehensive Molecular Analyses of Lung Adenocarcinoma with Regard to the Epidermal Growth Factor Receptor, K-ras, MET, and Hepatocyte Growth Factor Status
Takamitsu Onitsuka et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer
Heounjeong Go et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy
J. Rafael Sierra et al.
MOLECULAR CANCER (2010)
Roles of Sema4D and Plexin-B1 in tumor progression
Ewe Seng Ch'ng et al.
MOLECULAR CANCER (2010)
Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition
Simona Corso et al.
MOLECULAR CANCER (2010)
Acquired resistance to gefitinib: The contribution of mechanisms other than the T790M, MET, and HGF status
Takamitsu Onitsuka et al.
LUNG CANCER (2010)
MET signalling: principles and functions in development, organ regeneration and cancer
Livio Trusolino et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2010)
Search for Quark Compositeness with the Dijet Centrality Ratio in pp Collisions at √s=7 TeV
V. Khachatryan et al.
PHYSICAL REVIEW LETTERS (2010)
MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients
F. Cappuzzo et al.
ANNALS OF ONCOLOGY (2009)
The MET Receptor Tyrosine Kinase Is a Potential Novel Therapeutic Target for Head and Neck Squamous Cell Carcinoma
Tanguy Y. Seiwert et al.
CANCER RESEARCH (2009)
Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases
Fawn Qian et al.
CANCER RESEARCH (2009)
HGF and c-Met Participate in Paracrine Tumorigenic Pathways in Head and Neck Squamous Cell Cancer
Lynn M. Knowles et al.
CLINICAL CANCER RESEARCH (2009)
Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer
Joseph Paul Eder et al.
CLINICAL CANCER RESEARCH (2009)
Expression of Hepatocyte Growth Factor and Its Receptor Met in Wilms' Tumors and Nephrogenic Rests Reflects Their Roles in Kidney Development
Raisa Vuononvirta et al.
CLINICAL CANCER RESEARCH (2009)
Multitarget drugs: the present and the future of cancer therapy
Annalisa Petrelli et al.
EXPERT OPINION ON PHARMACOTHERAPY (2009)
Serum hepatocyte growth factor as a prognostic marker for stage II or III colorectal cancer patients
Yuji Toiyama et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Semaphorin signaling in cancer cells and in cells of the tumor microenvironment - two sides of a coin
Lorena Capparuccia et al.
JOURNAL OF CELL SCIENCE (2009)
Increased MET Gene Copy Number Negatively Affects Survival of Surgically Resected Non-Small-Cell Lung Cancer Patients
Federico Cappuzzo et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Plexin B1 is repressed by oncogenic B-Raf signaling and functions as a tumor suppressor in melanoma cells
G. M. Argast et al.
ONCOGENE (2009)
Clinicopathologic and Molecular Features of Epidermal Growth Factor Receptor T790M Mutation and c-MET Amplification in Tyrosine Kinase Inhibitor-resistant Chinese Non-small Cell Lung Cancer
Hua-Jun Chen et al.
PATHOLOGY & ONCOLOGY RESEARCH (2009)
Co-overexpression of Met and Hepatocyte Growth Factor Promotes Systemic Metastasis in NCI-H460 Non-Small Cell Lung Carcinoma Cells
Roya Navab et al.
NEOPLASIA (2009)
c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases
Zhao-Shi Zeng et al.
CANCER LETTERS (2008)
MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival
Hongkui Jin et al.
CANCER RESEARCH (2008)
Active Cancer Immunotherapy by Anti-Met Antibody Gene Transfer
Elisa Vigna et al.
CANCER RESEARCH (2008)
Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer
Katsuhiro Okuda et al.
CANCER SCIENCE (2008)
Gab1 but not Grb2 mediates tumor progression in Met overexpressing colorectal cancer cells
Isolde Seiden-Long et al.
CARCINOGENESIS (2008)
Single-Agent and Combination Therapeutic Strategies to Inhibit Hepatocyte Growth Factor/MET Signaling in Cancer
Luca Toschi et al.
CLINICAL CANCER RESEARCH (2008)
Molecular cancer therapy: Can our expectation be MET?
Cristina Migliore et al.
EUROPEAN JOURNAL OF CANCER (2008)
Expression and Mutational Analysis of MET in Human Solid Cancers
Patrick C. Ma et al.
GENES CHROMOSOMES & CANCER (2008)
Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages
Jose Rafael Sierra et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
MET gene copy number in non-small cell lung cancer: Molecular analysis in a targeted tyrosine kinase inhibitor naive cohort
Michele Beau-Faller et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Drug development of MET inhibitors: targeting oncogene addiction and expedience
Paolo M. Comoglio et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Cai-Hong Yun et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Prognostic significance of serum hepatocyte growth factor in clear cell renal cell carcinoma : comparison with serum vascular endothelial growth factor
Shuji Tanimoto et al.
JOURNAL OF MEDICAL INVESTIGATION (2008)
ErbB-2 and met reciprocally regulate cellular signaling via plexin-B1
Jakub M. Swiercz et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Silencing the MET oncogene leads to regression of experimental tumors and metastases
S. Corso et al.
ONCOGENE (2008)
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
James Bean et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling
Ultan McDermott et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Plexin-B1 mutations in prostate cancer
Oscar Gee-Wan Wong et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
The MET receptor tyrosine kinase in invasion and metastasis
Silvia Benvenuti et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2007)
c-Met activation in lung adenocarcinoma tissues: An immunohistochemical analysis
Yu Nakamura et al.
CANCER SCIENCE (2007)
Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype
Stephane Garcia et al.
HUMAN PATHOLOGY (2007)
Hypoxia-inducible factor-1α correlates with MET and metastasis in node-negative breast cancer
Helen H. W. Chen et al.
BREAST CANCER RESEARCH AND TREATMENT (2007)
Plexin-BI plays a redundant role during mouse development and in tumour angiogenesis
Pietro Fazzari et al.
BMC DEVELOPMENTAL BIOLOGY (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
An orally available small-molecule inhibitor of c-met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms
Helen Y. Zou et al.
CANCER RESEARCH (2007)
Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome
Udal S. Kammula et al.
CANCER LETTERS (2007)
Lung cancer cell lines harboring MET gene amplification are dependent on met for growth and survival
Bart Lutterbach et al.
CANCER RESEARCH (2007)
From Tpr-Met to Met, tumorigenesis and tubes
P. Peschard et al.
ONCOGENE (2007)
A novel one-armed anti-c-met antibody inhibits glioblastoma growth in vivo
Tobias Martens et al.
CLINICAL CANCER RESEARCH (2006)
A transforming MET mutation discovered in non-small cell lung cancer using microarray-based resequencing
Torstein Tengs et al.
CANCER LETTERS (2006)
Semaphorin 4D provides a link between axon guidance processes and tumor-induced angiogenesis
John R. Basile et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity
A Petrelli et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752
GA Smolen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Transcriptional targets of hepatocyte growth factor signaling and Ki-ras oncogene activation in colorectal cancer
IM Seiden-Long et al.
ONCOGENE (2006)
Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma
CT Miller et al.
ONCOGENE (2006)
Somatic mutations lead to an oncogenic deletion of Met in lung cancer
M Kong-Beltran et al.
CANCER RESEARCH (2006)
Semaphorin 4D/Plexin-B1 induces endothelial cell migration through the activation of PYK2, Src, and the phosphatidylinositol 3-kinase-Akt pathway
JR Basile et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Cancer therapy: can the challenge be MET?
S Corso et al.
TRENDS IN MOLECULAR MEDICINE (2005)
Sema4D induces angiogenesis through met recruitment by Plexin B1
P Conrotto et al.
BLOOD (2005)
c-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu
E Lengyel et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
The tumour-stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients
D Masuya et al.
BRITISH JOURNAL OF CANCER (2004)
Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair
CG Huh et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC
A Iwasaki et al.
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY (2004)
Met provides essential signals for liver regeneration
M Borowiak et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Targeting the tumor and its microenvironment by a dual-function decoy Met receptor
P Michieli et al.
CANCER CELL (2004)
Interplay between scatter factor receptors and B plexins controls invasive growth
P Conrotto et al.
ONCOGENE (2004)
Plexin-B1/RhoGEF-mediated RhoA activation involves the receptor tyrosine kinase ErbB-2
JM Swiercz et al.
JOURNAL OF CELL BIOLOGY (2004)
The hepatocyte growth factor regulatory factors in human breast cancer
C Parr et al.
CLINICAL CANCER RESEARCH (2004)
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene
S Pennacchietti et al.
CANCER CELL (2003)
Candidate tumor suppressor genes at FRA7G are coamplified with MET and do not suppress malignancy in a gastric cancer
SY Han et al.
GENOMICS (2003)
The Semaphorin 4D receptor controls invasive growth by coupling with Met
S Giordano et al.
NATURE CELL BIOLOGY (2002)
Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein
P Peschard et al.
MOLECULAR CELL (2001)
Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice
R Wang et al.
JOURNAL OF CELL BIOLOGY (2001)
c-MET expression in myofibroblasts -: Role in autocrine activation and prognostic significance in lung adenocarcinoma
M Tokunou et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
Expression of the hepatocyte growth factor/c-Met pathway is increased at the cancer front in breast carcinoma
G Edakuni et al.
PATHOLOGY INTERNATIONAL (2001)
Hepatocyte growth factor is predominantly expressed by the carcinoma cells in non-small-cell lung cancer
MS Tsao et al.
HUMAN PATHOLOGY (2001)
Over-expression of hepatocyte growth factor/scatter factor (HGF/SF) and the HGF/SF receptor (cMET) are associated with a high risk of metastasis and recurrence for children and young adults with papillary thyroid carcinoma
R Ramirez et al.
CLINICAL ENDOCRINOLOGY (2000)
A novel germ line juxtamembrane Met mutation in human gastric cancer
JH Lee et al.
ONCOGENE (2000)
Activation of hepatocyte growth factor-Met autocrine loop enhances tumorigenicity in a human lung adenocarcinoma cell line
S Yi et al.
NEOPLASIA (2000)
Signalling by semaphorin receptors: cell guidance and beyond
L Tamagnone et al.
TRENDS IN CELL BIOLOGY (2000)
分享论文
